Sugi Predict

Sugi Predict / Compounds / SCHEMBL17801236

SCHEMBL17801236

SCHEMBL17801236

Cn1cc(-c2cn3nc(C(=O)O)cc3c(O)n2)cn1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.47
▸ JAK2 O60674 6/20 0.43
▸ JAK1 P23458 6/20 0.43
▸ TYK2 P29597 6/20 0.43
▸ JAK3 P52333 5/20 0.43
▸ CCNC P24863 1/20 0.40
▸ CDK8 P49336 1/20 0.40
▸ PIM1 P11309 1/20 0.39
▸ PIM2 Q9P1W9 1/20 0.39
▸ GRM2 Q14416 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ STING1 Q86WV6 1/20 0.38
▸ BTK Q06187 2/20 0.37
▸ IRAK4 Q9NWZ3 2/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ CHRM1 P11229 1/20 0.35
▸ KDM5B Q9UGL1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21872222 0.87 CHEK1 (0.39) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL25236672 0.87 CHEK1 (0.39) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL24438940 0.84 CHEK1 (0.42) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL17801193 0.84 JAK2 (0.41) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL19253504 0.82 JAK2 (0.48) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL24438255 0.81 JAK2 (0.41) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL24060899 0.80 ERN1 (0.41) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL30038166 0.79 JAK2 (0.41) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL21033225 0.75 CHEK1 (0.50) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL24438005 0.74 GSK3B (0.53) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 — — EP disclosed
EP-4688778-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Biogen MA Inc. (US) 2026-02-11 — — EP disclosed
US-12404275-B2 Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof PRIMEGENE (BEIJING) CO., LTD. (CN) 2025-09-02 — — US disclosed
US-20250034150-A1 BTK INHIBITORS BIOGEN MA INC. 2025-01-30 — — US disclosed
WO-2024233642-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2024-11-14 — — WO disclosed
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
CN-118804915-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2024-10-18 — — CN disclosed
WO-2024211696-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES BIOGEN MA INC. (US) 2024-10-10 — — WO disclosed
EP-4429770-A1 BTK INHIBITORS Biogen MA Inc. (US) 2024-09-18 — — EP disclosed
CN-113924301-B Pyrazolopyrazine derivative compound, pharmaceutical composition and application thereof 北京普祺医药科技股份有限公司 2024-08-16 — — CN disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2018136661-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-07-26 — — WO disclosed
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-21 — — US disclosed
EP-3227297-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS Array Biopharma, Inc. (US) 2017-10-11 — — EP disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
WO-2016090285-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 CHEK1 1910/4885JAK2 849/4885JAK1 1320/4885
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 CHEK1 773/4885JAK2 3/4885JAK1 1/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 CHEK1 506/4885JAK2 2/4885JAK1 1/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 CHEK1 2027/4885JAK2 923/4885JAK1 1401/4885
US-20250034150-A1 BTK INHIBITORS BTK, SYK, LYN CHEK1 294/4885JAK2 6/4885JAK1 7/4885
US-12404275-B2 Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof JAK2, TYK2, JAK1 CHEK1 603/4885JAK2 1/4885JAK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.